Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06507306 · ClinicalTrials.gov registry record · Phase 1
A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies
A Phase 1 study of Solid Tumor, Adult, sponsored by Kumquat Biosciences.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 100
- Enrollment target
- 20
- Study locations
NCT06507306: Recruiting Phase 1 study of Solid Tumor, Adult, sponsored by Kumquat Biosciences.
NCT06507306 is a Phase 1 study of Solid Tumor, Adult that is actively recruiting participants, run by Kumquat Biosciences. The registered enrollment target is 100 participants, below the 189-participant average among 72 other Solid Tumor, Adult trials with a reported enrollment target (47% lower). The trial reports 20 study locations across 17 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06507306, a Phase 1 study of Solid Tumor, Adult, is actively recruiting participants, sponsored by Kumquat Biosciences.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 100 participants
- Enrollment target
- 20
- Study locations
Study Summary
The goal of this clinical trial is to learn if KQB198 works to treat advanced solid tumor cancer in adults. It will also learn about the safety of KQB198. The main questions it aims to answer are: * What is the safe dose of KQB198 by itself or in combination with other anti-cancer drugs? * Does KQB198 alone or in combination with other anti-cancer drugs decrease the size of the tumor? * What happens to KQB198 in the body? Participants will: * Take KQB198 daily, alone or in combination with another anti-cancer drug * Visit the clinic about 8 times in the first 8 weeks, and then once every 4 weeks after that
Primary Outcome
Safety characterized by type, incidence, severity, timing, seriousness and relationship to study treatment of AEs, SAEs, and DLTs, from first dose of study treatment to 28 days after last dose of study treatment.
Conditions Studied
Interventions
- DRUG Osimertinib
- DRUG Amivantamab
- DRUG KQB198
Study Locations (20)
Florida
- Sarah Cannon Research Institute at Florida Cancer Specialists - Lake Nona - - Orlando
- Florida Cancer Specialists - Sarasota - Sarasota
Texas
- MD Anderson Cancer Center - Houston
- New Experimental Therapeutics of San Antonio - NEXT Oncology - San Antonio
Other
- Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" - Naples
- Severance Hospital, Yonsei University Health System - Seoul
Colorado
- Sarah Cannon Research Institute at HealthONE - Denver
Michigan
- Henry Ford Health System - Detroit
New York
- David H. Koch Center for Cancer Center at Memorial Sloan Kettering Cancer Center - Long Island City
Ohio
- The Lindner Center for Research and Education at The Christ Hospital - Cincinnati
Tennessee
- Sarah Cannon and HCA Research Institute - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2024-06-03 |
| Est. Completion | 2027-01-31 |
| Phase | Phase 1 |
What NCT06507306 shows while recruiting
NCT06507306 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 189-participant average among 72 other Solid Tumor, Adult trials with a reported enrollment target (47% lower).
The record links to 1 condition, with Solid Tumor, Adult appearing as the primary indexed condition, and to 3 interventions - of which Osimertinib is the first listed.
NCT06507306 names 20 study sites across 17 states, led by Florida, Texas, Other.
Frequently Asked Questions
What is clinical trial NCT06507306 about?
NCT06507306 is a clinical study titled "A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies". The goal of this clinical trial is to learn if KQB198 works to treat advanced solid tumor cancer in adults. It will also learn about the safety of KQB198. The main questions it aims to answer are: * What is the safe dose of KQB198 by itself or in combination with other anti-cancer drugs? * Does KQB...
What is the current status of trial NCT06507306?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 100 participants. The study started on 2024-06-03. Estimated completion is 2027-01-31.
What conditions does trial NCT06507306 study?
This clinical trial studies the following conditions: Solid Tumor, Adult.
What interventions are being tested in trial NCT06507306?
The interventions under investigation include: Osimertinib (DRUG), Amivantamab (DRUG), KQB198 (DRUG).
Who is sponsoring clinical trial NCT06507306?
This trial is sponsored by Kumquat Biosciences, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06507306 being conducted?
This trial has 20 study locations across Colorado, Florida, Michigan, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumor, Adult
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06507306's enrollment target sits among peer trials
100 39th of 72 higher than 32 of 72 other Solid Tumor, Adult trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Solid Tumor, Adult trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
Open-Label, Dose-Escalation With Expansion to Assess the Safety, Tolerability, and PK of TRE-515 in Subjects With Solid Tumors
RECRUITING · Phase 1
-
A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
RECRUITING · Phase 1
-
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With Pembrolizumab
RECRUITING · Phase 1
-
A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI